North America Dominates the Global Prothrombin Complex Concentrate Market with a Share of 37.15%

Global Prothrombin Complex ConcentrateMarket Overview

According to Global Market Monitor, the global prothrombin complex concentrate market size is $879.05 million in 2024 with a CAGR of 4.65% from 2024 to 2029.

Regional Market

Because Prothrombin Complex Concentrate, which mainly takes human plasma as the raw material, is a scarce resource and is influenced by national policies and regulations for reasons of national security, management risks, and problems left over from history, it has a large supply gap in China and other developing countries and is a market with great demand. The adjustment of reimbursement policies for rare blood diseases and the expansion of related plasma collection centers in China and India will lead to a substantial increase in the demand for Prothrombin Complex Concentrate in the future. As an important economy in the developed world, Europe is also a potential market for Prothrombin Complex Concentrate, which has not yet been fully opened in Europe. The prevalence of congenital coagulation factor deficiency in Europe will increase the demand in the European market. The application of Prothrombin Complex Concentrate in North America is the highest in the world, and the supply of raw materials is also the most abundant. The market in North America will be further opened due to the increasing cooperation between the major player and distributor, the United States, and the increasingly wide application range.

Market Drivers

Clinical studies have demonstrated that fresh frozen plasma requires longer infusion times than prothrombin complex concentrate (PCC). In addition to infusion time, prothrombin complex concentrate has other advantages over FFP. Some of the remarkable properties that have led to the increasing adoption of prothrombin complex concentrates are their ability to undergo remodeling in a short period of time. In addition to the above factors, the better safety of prothrombin complex concentrate affects the user's preference for fresh frozen plasma.

Since its FDA approval, Kcentra has been adopted by many healthcare professionals worldwide. Kcentra has proved effective in restoring blood clotting because it contains certain factors that help replenish various clotting factors. Kcentra plays an important role in the treatment of patients treated with warfarin. Warfarin can cause severe and acute blood loss and minimize such loss and recovery factors, and Kcentra has been shown to be beneficial. Therefore, the use of PCC in warfarin induced bleeding has led to an increase in the adoption rate, which in turn has driven the development of the global market.

The latest update on the licensing policy for prothrombin complex concentrate bodes well for development. Globally, there has been a relaxation in the use of PCC in the treatment of hemorrhagic disorders. In addition, increased government funding to promote the use of PCC in surgical procedures is driving the global market. The effective clinical efficiency of PCC has encouraged governments around the world to promote the use of PCC to treat unnecessary bleeding during surgery.

Drivers	Better than fresh frozen plasma
	The scope of application is extended to the whole world
	Relaxation of policy
Limitations	Plasma supply is less than demand
	Blood collection irregularities in developing countries